BI Asset Management Fondsmaeglerselskab A S Has $14.71 Million Position in Cencora, Inc. $COR

Key Points

• BI Asset Management cut its Cencora stake by 69.8% in the fourth quarter, selling 100,735 shares and leaving it with 43,552 shares worth about $14.71 million.
• Other major institutions remain heavily invested in Cencora, with firms like Vanguard, State Street, Geode, JPMorgan, and Boston Partners increasing or maintaining large positions. Overall, 97.52% of Cencora’s stock is held by institutional investors and hedge funds.
• Cencora reported quarterly EPS and revenue below analyst estimates, though it still raised its FY2026 guidance and announced a $2 billion share repurchase program plus a quarterly dividend of $0.60 per share.

BI Asset Management Fondsmaeglerselskab A S reduced its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 69.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,552 shares of the company's stock after selling 100,735 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Cencora were worth $14,710,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company's stock valued at $7,976,681,000 after buying an additional 221,570 shares in the last quarter. State Street Corp boosted its position in Cencora by 9.3% in the third quarter. State Street Corp now owns 9,190,316 shares of the company's stock valued at $2,872,249,000 after buying an additional 782,911 shares in the last quarter. Geode Capital Management LLC boosted its position in Cencora by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company's stock valued at $1,843,268,000 after buying an additional 169,055 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company's stock valued at $1,461,965,000 after buying an additional 821,098 shares in the last quarter. Finally, Boston Partners boosted its position in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company's stock valued at $1,409,152,000 after buying an additional 89,506 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on COR. Leerink Partners restated an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research report on Tuesday, February 10th. Wells Fargo & Company reduced their target price on shares of Cencora from $429.00 to $331.00 and set an "overweight" rating on the stock in a research report on Monday, May 11th. Weiss Ratings lowered shares of Cencora from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, May 22nd. Finally, Robert W. Baird reduced their target price on shares of Cencora from $420.00 to $339.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $380.25.

Cencora Price Performance

Shares of COR stock opened at $274.94 on Friday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The firm's 50 day moving average is $292.70 and its 200-day moving average is $330.55. The firm has a market capitalization of $53.49 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the prior year, the company earned $4.42 earnings per share. The company's quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts forecast that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora's dividend payout ratio is currently 18.40%.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.